Cardiff Oncology Inc

Cardiff Oncology is a clinical-stage biotechnology company focused on developing novel cancer therapies through PLK1 inhibition, a validated oncology target. Its lead asset, onvansertib, is a highly specific oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large underserved patient population. The company is advancing toward a planned registrational Phase 3 trial following a successful End-of-Phase 2 meeting with the FDA. Onvansertib is also under investigation in other PLK1-driven cancers through investigator-initiated trials and has shown preclinical activity in combination with antibody-drug conjugates. The company generates minimal royalty revenue and is primarily funded through equity offerings. Cardiff Oncology is currently involved in litigation with its licensor, Nerviano Medical Sciences, regarding the license agreement for onvansertib, which introduces material risk to its core program. Updated Aug 11, 2026